News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I - MRX-I Targets Multi-Drug Resistant Gram Positive Infections


3/15/2010 10:30:30 AM

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

MRX-I: A Safer Oxazolidinone Antibiotic

Multi-Drug Resistance: A Growing Global Public Health Crisis

About MicuRx Pharmaceuticals, Inc.

MicuRx Pharmaceuticals, Inc.




Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES